3/23/2009 | SS | Endo Pharmaceuticals buys Indevus for $370 million
|
3/19/2009 | SS | Endo Pharmaceuticals accepts 89% of Indevus shares in completed tender offer
|
3/2/2009 | SS | Endo Pharmaceuticals extends subsequent offering period for remaining Indevus shares
|
2/23/2009 | SS | Endo Pharmaceuticals begins subsequent offer for remaining Indevus shares
|
2/5/2009 | SS | Indevus settles lawsuits, agrees to lower termination fee in proposed merger with Endo
|
1/6/2009 | SS | Market Commentary: Endo buyout likely to close; Rohm & Haas stock falls below Dow bid; Johnson & Johnson extends offer
|
1/5/2009 | SS | Endo Pharmaceuticals to buy Indevus for $370 million
|
8/26/2008 | HYPV | New Issue: Indevus closes $105 million private placement of 16% non-recourse notes
|
6/4/2008 | CV | Market Commentary: Pioneer Natural gains on investor switch; Lehman trades below par; Indevus slides
|
8/7/2007 | CV | Indevus accepts tenders for 99.9% of notes in exchange offer for 6.25% convertibles
|
7/6/2007 | CV | Indevus announces exchange offer for 6.25% convertibles
|
4/12/2007 | SS | Indevus, Valera set exchange rate at 1.1337 in $120 million merger deal slated to close April 17
|
10/13/2006 | BT | JMP reiterates Indevus at strong buy
|
9/26/2006 | BT | Indevus ends phase 2 pagoclone trial over lack of drug effect
|
9/26/2006 | BT | JMP reiterates Indevus at strong buy
|
9/26/2006 | BT | Market Commentary: AnorMED rockets on Millennium bid but still seen in play; Genzyme mum; Indevus slips on trial's end
|
8/3/2006 | BT | Market Commentary: Titan zooms; Vanda slides; LAB goes public in Canada; Indevus up, NitroMed dives
|
8/3/2006 | BT | Indevus reports second-quarter revenues up 45% at $11.9 million
|
8/3/2006 | BT | Indevus reiterated at strong buy by JMP
|
7/24/2006 | BT | Market Commentary: Genitope falls 12%; Micromet off; Oscient up; DepoMed dives; Atricure off; Discovery Labs rises 10%
|
7/10/2006 | BT | JMP reiterates Indevus at strong buy
|
7/7/2006 | BT | Market Commentary: LifeCell lower; CV Therapeutics loses 2%; Indevus up; Tercica off by 8%; Amarillo Biosciences off
|
7/7/2006 | BT | Indevus second phase 3 trial of Sanctura XR for overactive bladder meets primary endpoints
|
6/30/2006 | BT | Indevus Pharmaceuticals greenshoe fully exercised, raising offer to 8.05 million shares
|
6/28/2006 | BT | New Issue: Indevus raises $32.55 million in spot follow-on of 7 million shares at $4.65 each
|
6/28/2006 | BT | Market Commentary: Replidyne debut shaky but closes in the green; Indevus rises in face of spot sale; Depomed loses 3%
|
6/23/2006 | BT | Indevus begins phase 2 trial for Pagoclone in premature ejaculation
|
6/22/2006 | BT | Indevus completes enrollment in pharmacokinetic trial for its testosterone preparation Nebido
|
6/16/2006 | BT | JMP reiterates Indevus at strong buy
|
6/15/2006 | BT | Indevus: Sanctura XR for overactive bladder meets endpoints in phase 3 trial
|
5/31/2006 | BT | JMP starts Indevus with strong buy
|
5/24/2006 | BT | Indevus announces positive top line results in phase 2 study of pagoclone in stuttering
|
5/8/2006 | BT | Indevus to announce results of Sanctura XR phase 3 test next month
|
3/21/2006 | BT | Indevus completes enrollment in second phase 3 trial for Sanctura XR
|
3/9/2006 | BT | FDA accepts Indevus IND for Nebido for male hypogonadism
|
3/7/2006 | BT | Indevus files patent application for pagoclone as treatment for premature ejaculation
|
3/6/2006 | BT | Indevus completes enrollment in phase 3 trial of pagoclone, first phase 2 trial of Sanctura XR
|
2/17/2006 | BT | Market Commentary: Cytyc shares, convertibles gain big; Alkermes slips on FDA news; NPS Pharma off amid uncertainty
|
1/3/2006 | BT | Market Commentary: Adams declines; Alkermes gains; Cephalon up; Indevus off; Wyeth up, Bradley off, ViroPharma rises
|
12/30/2005 | BT | Indevus Pharmaceuticals files 10 million share stock shelf
|
12/20/2005 | BT | Market Commentary: Connetics rebounds to end higher; SeraCare plunges 48%; OraSure gains 8%; CuraGen rises by 4%
|
12/13/2005 | BT | Market Commentary: CuraGen sinks; Indevus soars; Voyager pulls IPO; Insmed up on FDA approval; Tercica falls
|
12/13/2005 | BT | Savient agrees to sell testosterone product Delatestryl to Indevus for $5 million, share of sales
|
11/21/2005 | BT | Market Commentary: Incyte zooms on R&D pact with Pfizer; Medicis, Mentor, Allergan, Inamed tangle in merger scuffle
|
11/10/2005 | BT | Market Commentary: King Pharma off, Pain increases; ViroPharma falls on generic risk; Eyetech, OSI seesaw on merger
|
10/31/2005 | BT | Market Commentary: NeoPharma skyrockets on new CEO; Charles River Labs higher; Nabi, Indevus, Invitrogen up
|
10/25/2005 | BT | Market Commentary: Indevus spikes on trial; Idenix off big on follow-on sale; Rigel up on Serono pact; Sepracor rises
|
10/19/2005 | BT | Market Commentary: Predix IPO on deck; Indevus up; Generex up; NeoPharm gains; Amgen plunges; Genta climbs
|
7/21/2005 | BT | Market Commentary: Adams IPO zooms; Accentia stalls, again; Guilford up on MGI Pharma merger; Momenta on tap; Isis rises
|
7/14/2005 | BT | Market Commentary: Genentech active; CryoCor IPO trades up, sinks; Mylan prices tight, center; BioMarin off on follow-on
|
6/15/2005 | BT | Indevus Pharmaceuticals reports positive trial results for overactive bladder drug Sanctura XR
|
1/27/2005 | CV | Market Commentary: Open Solutions higher in gray market; Rambus quiet, last seen at 98.5 offer; Rite Aid edges up
|
3/25/2004 | CV | Market Commentary: Chesapeake Energy lags other new paper at par; Grey Wolf talked at reoffer price of 99
|
7/11/2003 | CV | New Issue: Indevus upsized $60 million convertible yields 6.25%, up 30%
|
7/7/2003 | CV | Indevus launches $50 million convertible, talked to yield 5.25-5.75%, up 25-30%
|
7/7/2003 | CV | Market Commentary: HealthSouth converts bid up some 20 points on financials; trading sees post-holiday lull
|